A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-20SP, an Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy Targeting CD20 in Subjects with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Latest Information Update: 28 Mar 2025
At a glance
- Drugs LUCAR 20SP (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 21 Jun 2024 New trial record